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Abstract
Introduction Biological markers that reliably predict clinical or
pathological response to primary systemic therapy early during
a course of chemotherapy may have considerable clinical
potential. This study evaluated changes in Ki-67 labeling index
and apoptotic index (AI) before, during, and after neoadjuvant
anthracycline chemotherapy.
Methods Twenty-seven patients receiving neoadjuvant FEC (5-
fluorouracil, epirubicin, and cyclophosphamide) chemotherapy
for operable breast cancer underwent repeat core biopsy after
21 days of treatment. Tissue from pre-treatment biopsy, day 21
and surgery was analysed for Ki-67 index and AI.
Results The objective clinical response rate was 56%. Eight
patients (31%) achieved a pathological response by histological
criteria; two patients had a near-complete pathological
response. A reduction in Ki-67 index was observed in 68% of
patients at day 21 and 72% at surgery; Ki-67 index increased
between day 21 and surgery in 54%. AI decreased in 50% of
tumours by day 21, increased in 45% and was unchanged in
one patient; 56% demonstrated rebound increases in AI by the
time of surgery. Neither pre-treatment nor post-chemotherapy
median Ki-67 index nor median AI at all three time points or
relative changes at day 21 and surgery differed significantly
between clinical or pathological responders and non-
responders. Clinical responders had lower median Ki-67 indices
at day 21 (11.4% versus 27.0%, p = 0.02) and significantly
greater percentage reductions in Ki-67 at day 21 than did non-
responders (-50.6% versus -5.3%, p = 0.04). The median day-
21 Ki-67 was higher in pathological responders (30.3% versus
14.1%, p = 0.046). A trend toward increased AI at day 21 in
pathological responders was observed (5.30 versus 1.68, p =
0.12). Increased day-21 AI was a statistically significant
predictor of pathological response (p = 0.049). A strong trend
for predicting pathological response was seen with higher Ki-67
indices at day 21 and AI at surgery (p  = 0.06 and 0.06,
respectively).
Conclusion The clinical utility of early changes in biological
marker expression during chemotherapy remains unclear. Until
further prospectively validated evidence confirming the reliability
of predictive markers is available, clinical decision-making
should not be based upon individual biological tumour marker
profiles.
Introduction
Primary breast carcinomas treated with neoadjuvant chemo-
therapy or primary systemic therapy (PST) provide an ideal
model to evaluate the role of biological markers as predictive
and prognostic factors. Many retrospective studies have iden-
tified patterns of biomarker expression before or after chemo-
therapy which have predictive or prognostic significance in
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relation to different clinical endpoints. However, no single pre-
treatment marker that can accurately predict response to PST
has been found to be of clinical utility to date. Despite high
objective response rates to PST, a small proportion of patients
will fail to respond or will progress during primary chemother-
apy. The early identification of non-responders may spare
these patients the unnecessary toxicity of ineffective chemo-
therapy and allow them to be offered alternative treatment
strategies or non-cross-resistant regimens. Biological markers
that can reliably predict clinical or pathological response early
during a course of treatment therefore have considerable clin-
ical potential.
In randomised clinical trials, PST confers equivalent survival
and increased breast conservation rates compared with pri-
mary surgery and adjuvant cytotoxic chemotherapy [1,2].
Complete pathological response (pCR) is a strong prognostic
indicator for prolonged disease-free and overall survival [3].
Patients achieving a complete clinical response (cCR) also
have a statistically superior disease-free and overall survival
advantage over clinical non-responders [3,4]. It should be
acknowledged that in the smaller of these two studies [4],
patients received some chemotherapy post-operatively. Clini-
cal response is frequently used as a surrogate intermediate
endpoint for predicting disease-free survival and outcome
after primary chemotherapy; pCR is a valid intermediate surro-
gate endpoint for predicting overall survival.
The ability to biopsy breast tumours in situ during primary
chemotherapy provides a unique opportunity to evaluate
molecular markers in the tumour before and during treatment
and to relate these changes to both clinical and pathological
response. Immunohistochemical analysis of tumour material
from repeat biopsies during treatment may therefore help
unravel the complex molecular mechanisms that ultimately
determine clinical outcomes and thereby provide more useful
and reliable intermediate predictive and prognostic factors.
The nuclear antigen Ki-67 is a proliferation marker expressed
only in cycling cells. A strong correlation between S-phase
fraction and Ki-67 index has been demonstrated [5-7]. Conse-
quently, quantitative assessment of Ki-67 staining on paraffin-
embedded tumour sections provides an accurate estimate of
the proliferation index of individual tumours. Cytotoxic chemo-
therapy induces programmed cell death by apoptosis. The
percentage of apoptotic cells in tumour sections may be
measured by labeling fragmented DNA breaks and calculating
the apoptotic index (AI) using the TUNEL (terminal transferase
uridyl nick-end labeling) assay [8].
In this study, Ki-67 and apoptosis were assessed on histolog-
ical material before, during, and after PST for operable breast
cancer to evaluate whether early changes in proliferation or
apoptosis predict clinical or pathological response to
treatment.
Materials and methods
Treatment protocol
A series of 39 female patients with operable (T2–T4, N0 or
N1, M0) invasive primary breast carcinoma were identified
between May 1999 and July 2001. Patients with metastatic
disease (M1) or inflammatory breast cancer (T4d) were
excluded. Core biopsy of the primary tumour was performed at
diagnosis and repeated on day 21, immediately prior to the
second cycle of chemotherapy. Six cycles of FEC chemother-
apy (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, and
cyclophosphamide 600 mg/m2) were administered at 21-day
intervals. Bi-dimensional clinical tumour measurements were
recorded before every treatment. Four patients developed dis-
ease progression by clinical criteria during chemotherapy and
proceeded to immediate surgery. The remaining women
underwent breast-conserving surgery or mastectomy at the
surgeon's discretion approximately 1 month after the final
cycle of chemotherapy. All patients who were treated by
breast-conserving surgery received post-operative radiation to
the residual breast (40 Gy in 15 daily fractions plus 10-Gy
boost to tumour bed in five fractions; n = 12) plus or minus
lymph nodes (50 Gy in 25 fractions for a period of 5 weeks; n
= 2). Post-mastectomy chest wall radiation was delivered to
13 of 15 patients (11 chest wall only, 2 chest wall and nodes).
No patient received post-operative chemotherapy. Women
with oestrogen receptor (ER)-positive tumours received 5
years of adjuvant tamoxifen (20 mg daily) starting after surgery.
The study was approved by the Luton & Dunstable NHS
(National Health Service) Trust Ethics Committee and con-
ducted in accordance with the Helsinki Declaration.
Assessment of response
Clinical response
Standard UICC (International Union Against Cancer) criteria
were used to define objective clinical response [9]. Changes
in the calculated product of bi-dimensional tumour measure-
ments on two successive evaluations were recorded at each
visit. Complete response (CR) was defined as no residual pal-
pable abnormality, partial response (PR) as greater than 50%
tumour shrinkage, stable disease (SD) as less than 50%
tumour shrinkage or no change, and progressive disease as an
increase of at least 25%.
Pathological response
Although many different systems for grading pathological
response have been proposed [10-15], no standard method
for pathological assessment after chemotherapy has been
adopted. A previously described simple scoring system that
can be applied in clinical practice was therefore employed
[16]. A consultant histopathologist (P.I. Richman) blinded to
clinical outcome reviewed all paired biopsy and surgical spec-
imens. We defined 'histological tumour response' by both (a)
an apparent reduction in tumour cell/stroma ratio and (b) one
or more chemotherapy-induced cytological changes (that is,Available online http://breast-cancer-research.com/content/8/3/R31
Page 3 of 10
(page number not for citation purposes)
enlarged cells with finely vacuolated cytoplasm, an enlarged
vesicular nucleus with a prominent single eosinophilic nucleo-
lus, or an enlarged hyperchromatic dense nucleus with an
irregular outline). The following classification was used to
score surgical specimens for pathological response: CR, no
residual invasive carcinoma; PR, residual invasive carcinoma
with histological tumour response; and SD, residual invasive
carcinoma with no histological tumour response.
Immunohistochemical technique
Four-micrometer sections were dried overnight at 37°C. Prior
to antibody staining, the slides were pre-treated with micro-
Table 1
Patient characteristics
n Percentage
Age: median 51 years
Age: range 29–65
Menstrual status Pre 14 52
Peri 6 22
Post 7 26
Clinical TNM stage at diagnosis T2 12 44
T3 13 48
T4 2 7
Clinical node status N0 17 63
N1 10 37
Breast Right 15 56
Left 12 44
Breast surgery Wide excision 12 44
Mastectomy 15 56
Postoperative radiotherapy Nil 2 7
Breast 12 44
Chest wall 13 48
ER status (biopsy) ER-positive 15 56
ER-negative 12 44
HER-2 status (biopsy) HER-2-positive 11 41
HER-2-negative 16 59
Tumour grade Unknown* 5 19
G1 2 7
G2 9 33
G3 11 41
Pathological T stage pCR 0 0
pT1 8 30
pT2 17 63
pT3 2 7
Pathological N stage pN0 11 41
pN1 12 44
pNX 4 15
*Grading not possible due to chemotherapy artefact. ER, oestrogen receptor; HER-2, human epidermal growth factor 2; TNM, tumour, node, 
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wave irradiation to unmask binding epitopes. After blocking of
endogenous peroxidase activity with a 3% solution of hydro-
gen peroxide in methanol for 30 minutes, slides were
immersed in 200 ml of 10 mM citric acid (pH 6.0) for 4 minutes
on high power (800 W). After topping up of the buffer with dis-
tilled water, this step was repeated. The slides were then left
to stand for 10 minutes in buffer at room temperature before
being washed thoroughly in tap water. After three washes in
tris-buffered saline (TBS), the slides were incubated with a
1:200 dilution of rabbit anti-Ki-67 polyclonal antibody (A0047;
Dako UK Ltd., Cambridgeshire, UK) in TBS for 1–2 hours at
room temperature. After three more washes in TBS, bioti-
nylated goat anti-rabbit (Ki-67) in TBS was applied for 1 hour
at room temperature. After an additional three washes, ABC
complex (K0355; Dako UK Ltd.) was added for 1 hour at room
temperature. The staining was visualised by adding diami-
nobenzidine (DAB kit SK 4100; Vector Laboratories, Burling-
ton, CA, USA) for 5 minutes at room temperature. The slides
were washed well in tap water and counterstained with May-
ers haematoxylin for 10 seconds to 1 minute and then dehy-
drated, cleared, and mounted in distrene plasticiser xylene
(DPX). Positive and negative controls were performed with
each batch of slides. Paired core biopsies and surgical speci-
mens from the same patient were stained on the same run.
Apoptotic cells were visualised using a commercial end labe-
ling (TUNEL) assay previously described [8]. Briefly, endog-
enous peroxidase activity was inactivated with 1% hydrogen
peroxide in phosphate-buffered saline (PBS) (pH 7.4) for 10
minutes. Nuclei of tissue sections were stripped of proteins by
incubation with 0.5% pepsin (pH 2.0) (Sigma Chemical Co,
Poole, Dorset, UK) for 30 minutes at 37°C. The sections were
washed five times in distilled water to remove all traces of pep-
sin. Each section undergoing the TUNEL protocol was incu-
bated for 5 minutes in Tris buffer (pH 7.6) and then for 1 hour
at 37°C in 100 µl of reaction mixture consisting of 15 units TdT
FPLC pure (Pharmacia, Windsor, Berkshire, UK), 0.5 nmol
biotin-16-dUTP (Boehringer Mannheim, Mannheim, Germany),
5 mM cobalt chloride, 0.2 M sodium cacodylate, 25 mM Tris
HCl (pH 6.6), and 0.25 mg/ml bovine serum albumin (BSA)
dissolved in distilled water. After extensive washing in distilled
water, the sections were incubated for 30 minutes at room
temperature in 1:400 dilution of horseradish peroxidase con-
jugated to streptavidin (Dako UK Ltd.) in PBS supplemented
with 1% BSA and 0.5% Tween 20. Colour was developed for
10 minutes using 0.05% diaminobenzidine plus 0.07% imida-
zole plus 0.1% hydrogen peroxide and further intensified in
0.5% copper sulphate with 0.9% sodium chloride for 1
minute. The sections were counterstained in Mayers haema-
toxylin, dehydrated, cleared in xylene, and mounted in DPX.
Scoring methods
Immunohistochemical scoring was performed without prior
knowledge of the clinical response. Ki-67 score was counted
on a minimum of 10 randomly selected ×40 high-power fields
containing representative sections of tumour and calculated
as the percentage of positively stained cells to total cells. The
AI was assessed by counting at least 3,000 malignant cells at
×400 magnification. Stained apoptotic cells were recorded,
and cells displaying classic apoptotic morphology but not
staining were also incorporated in the AI. Non-staining apop-
totic cells were recognised in the midst of cells with normal
morphology by having either condensed, irregular nuclei fre-
quently with a crescent-shaped appearance or fragmented
nuclei within cells showing cytoplasmic withdrawal. Areas with
extensive necrosis were avoided.
Statistical methods
Statistical analysis was carried out using JMP version 5.0
(SAS Institute Inc., Cary, NC, USA). Associations between
ordinal variables were assessed using χ2 analyses or the
Fisher exact test in the case of two-by-two variables. Analyses
involving Ki-67 and AI as continuous variables were investi-
gated using analysis of variance. A logistic regression analysis
was performed.
Results
Day-21 biopsy
Sufficient invasive carcinoma suitable for immunohistochemi-
cal analysis was present in 27 of the 39 day-21 biopsies. The
remaining 12 patients were excluded from the analysis: eight
yielded no demonstrable invasive tumour on day-21 biopsy,
two comprised high-grade DCIS (ductal carcinoma in situ)
only (presumably due to geographical miss), and two con-
tained tiny foci of invasive tumour deemed too small to reliably
interpret immunohistochemical staining.
Patient demographics
Of the 27 evaluable patients, 52% were pre-menopausal.
Most tumours were grade 2 (33%) or 3 (41%), stage T2
(44%) or T3 (42%), and clinically node-negative (63%) before
treatment. Fifty-six percent were ER-positive and 41% HER-2
(human epidermal growth factor-2)-positive. The patient char-
acteristics are shown in Table 1.
Response rates
All 27 patients were evaluable for clinical response on comple-
tion of chemotherapy. Surgical blocks were retrieved for
pathological scoring in 26 cases. The objective clinical
response rate (CR + PR) was 56% (15/27). Four patients
(15%) progressed by clinical criteria after two, two, four, and
six cycles of chemotherapy, respectively, and proceeded to
immediate surgery. The remaining eight patients (30%) had
clinically stable disease on completion. Eight patients (30%)
achieved a pathological response by histological criteria.
There were no complete pathological responders, although
two women had a 'near-pCR' with residual foci of invasive car-
cinoma measuring 1 and 2 mm in maximum dimension,
respectively.Available online http://breast-cancer-research.com/content/8/3/R31
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Biological markers before, during, and after 
chemotherapy
The median and range of Ki-67 indices before chemotherapy,
at day 21, and after treatment were 27.9% (4.1%–43.9%),
17.3% (4.1%–44.8%), and 21.7% (2.4%–50.4%), respec-
tively. The apoptotic indices at baseline, day 21, and surgery
were 1.92% (0.23%–5.4%), 1.69% (0.33%–11.2%), and
2.19% (0.9%–4.9%), respectively. At each time point, there
was a significant positive relationship between these two
parameters: the correlation coefficients were 0.47 (p  =
0.026), 0.65 (p = 0.0005), and 0.66 (p = 0.0014) in the
biopsy, day-21 and surgery samples, respectively.
Changes in biological markers during and after 
chemotherapy
A reduction in Ki-67 index from pre-treatment values was
observed in 63% (17/27) of patients at day 21 and 69% (18/
26) at surgery (Figure 1); there was no tumour material availa-
ble for one patient at surgery. Eleven patients demonstrated
sequential reductions in Ki-67 LI throughout the two study
periods, and four patients showed sequential increases during
therapy. Four of the 17 tumours that showed a reduction in LI
between biopsy and day 21 showed increases in proliferation
between day 21 and surgery. Of the 10 tumours that showed
no change or an increase in Ki-67 LI during the first 3 weeks
of chemotherapy, half displayed a subsequent reduction
between day 21 and surgery.
The AI was more difficult to assess in this material. There were
seven instances in the day-21 biopsies and nine in the surgical
material in which it was not possible to make a reliable meas-
urement with the TUNEL assay. In those cases that were eval-
uable, there was a wide variation in percentage change in AI
at day 21 compared with pre-treatment levels. AI decreased in
50% (10/20), increased in 45% (9/20), and was unchanged
in one patient (Figure 2). Overall, between initial biopsy and
surgery, a similar pattern was seen with eight (47%) out of 17
patients, with successful staining showing a reduction in AI.
Between day 21 and surgery, the majority of tumours (10 of
18) increased in apoptotic activity (Figure 2). Unlike in the Ki-
67 LI data, there was no consistent pattern in apoptosis
throughout treatment.
Ki-67 and clinical and pathological response
Neither pre-treatment nor post-chemotherapy median Ki-67
index differed significantly between clinical or pathological
responders and non-responders. Clinical responders
(CR+PR) had significantly lower median Ki-67 indices at day
21 than did non-responders (11.4% versus 27.0%, p = 0.02).
A similar trend for lower day-21 Ki-67 in patients achieving a
cCR was also recorded (p = 0.10). Clinical responders exhib-
ited significantly greater percentage reductions in Ki-67 at day
21 than did non-responders (-50.6% versus -5.3%, p = 0.04).
A decrease or no change in day-21 Ki-67 was observed in
80% (12/15) of clinical responders compared with 58% (7/
12) of non-responders (Figure 1). In the 11 patients who
showed sequential reductions in Ki-67 throughout the study
Figure 1
Changes in Ki-67 LI during treatment and clinical and pathological  response Changes in Ki-67 LI during treatment and clinical and pathological 
response. The data are expressed as % change between initial biopsy 
and day 21 relative to the initial biopsy score (x-axis) versus % change 
between day 21 and surgery relative to the day 21 index. (● ) repre-
sents patients with a complete clinical response, (● ) with a partial 
response and (❍ ) represents no response. The asterisks represent 
those patients who achieved a pathological response.
Figure 2
Changes in apoptotic LI during treatment and clinical and pathological  response Changes in apoptotic LI during treatment and clinical and pathological 
response. The data are expressed as % change between initial biopsy 
and day 21 relative to the initial biopsy score (x-axis) versus % change 
between day 21 and surgery relative to the day 21 index. (● ) repre-
sents patients with a complete clinical response, (● ) with a partial 
response and (❍ ) represents no response. The asterisks represent 
those patients who achieved a pathological response.Breast Cancer Research    Vol 8 No 3    Burcombe et al.
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period, nine (82%) achieved a clinical response (p = 0.019)
(Figure 1).
Paradoxically, the median day-21 Ki-67 was higher in patho-
logical responders (30.3% versus 14.1%, p = 0.046). There
were no association between pathological response and
changes in Ki-67 throughout the study period and no correla-
tion between clinical and pathological responses (Figure 1).
AI and clinical and pathological response
Median AI at all three time points and relative changes at day
21 and surgery did not differ significantly between clinical and
pathological responders or non-responders (Figure 2). How-
ever, there was a trend toward higher pre-treatment AI in path-
ological responders (2.72 versus 1.65, p  = 0.10). A non-
significant trend toward increased apoptosis at day 21 in path-
ological responders was also observed (5.30 versus 1.68, p =
0.12). No pattern in the distribution of changes in day-21 AI
emerges between clinical and pathological responders when
the data are represented graphically.
Biological characteristics of complete or 'near-complete' 
pathological responders
The ability to predict pCR, arguably the most useful endpoint
of all, could not be assessed in this cohort, because no patient
achieved a pCR. However, two patients had only tiny foci of
residual invasive carcinoma demonstrable after chemotherapy.
Both these 'near-pCR' patients had a very high AI at operation
(3.96 and 3.61), significantly greater than patients not achiev-
ing a 'near-pCR' (p = 0.04). One of these two patients was
evaluable for day-21 AI; a large increase in AI was seen (5.3
versus 3.86) after the first cycle of chemotherapy. No clear
trend in changes in Ki-67 during or after treatment was seen
in the two patients with excellent pathological tumour
regression.
Logistic regression analysis for prediction of response 
by different modalities of assessment
Logistic regression analyses were performed to establish
which, if any, of the biological marker variables measured at
different time points could predict response outcomes by
clinical, radiological, or pathological criteria (Table 2).
Increased AI at day 21 was a statistically significant predictor
of pathological response (p = 0.049). Similarly, greater Ki-67
indices at day 21 and higher AI at surgery displayed a strong
trend for predicting pathological response (p = 0.06 and 0.06,
respectively). Reductions in Ki-67 and AI at day 21 were
strongly predictive of better clinical response by UICC cate-
gory (p = 0.01 and 0.02, respectively). No significant associa-
tions were observed between the various biological markers
and clinical CR or radiological response assessed by mam-
mography and/or ultrasound. Low baseline AI was associated
with poor worst radiological response (p = 0.04).
Discussion
The prognostic significance of pre-treatment Ki-67 index in
breast tumours varies. Intuitively, rapidly proliferating tumours
confer a poor prognosis, and the majority of studies confirm
this association [17-26]. In some series, breast tumours with a
high proliferative index have a worse prognosis despite endo-
crine treatment [27,28] or chemotherapy [29]. However, other
authors report no significant difference in outcome after chem-
otherapy or hormone treatment in patients with rapidly prolifer-
ating tumours compared with those with more slowly growing
tumours [30-33].
Changes in tumour cell proliferation before and after pre-oper-
ative treatment have also been evaluated. A reduction in Ki-67
index has been demonstrated after chemotherapy [30,34,35],
tamoxifen therapy [31,36], and chemoendocrine therapy
[37,38]. More recently, studies have focused on the evaluation
of early changes in cell proliferation during treatment by ana-
lysing Ki-67 index in repeat tumour samples taken at varying
intervals during chemotherapy. Two studies at the Royal
Marsden Hospital (London, UK) performed on cytological
material obtained from fine needle aspiration (FNA) during
chemoendocrine treatment showed that reductions in Ki-67
proliferation index after 10, 14, or 21 days significantly predict
clinical response [37,38]. However, Billgren and colleagues
demonstrated that a decrease of more than 25% in proliferat-
ing fraction after the first course of chemotherapy significantly
predicted a reduced risk of disease recurrence (p = 0.033)
but showed no correlation with local objective response [39].
Multivariate analysis revealed that the decrease in proliferating
fraction significantly added prognostic information to lymph
node status. In a similar study, patients who responded to neo-
adjuvant chemotherapy and concurrent tamoxifen were found
to be more likely to have a reduction in Ki-67 ten days after
chemotherapy than were non-responders [40]. Post-treatment
Ki-67 index is also of prognostic importance: In a series of 42
patients treated with primary chemotherapy, high proliferative
index in residual tumour was associated with a worse disease-
free survival [41].
In this study, there was no significant difference in baseline Ki-
67 or AI between responders and non-responders assessed
by clinical, pathological, or radiological criteria. Both pre-treat-
ment and post-chemotherapy cell proliferation and apoptosis
failed to predict response by any modality of assessment.
More than two thirds of tumours exhibited a decrease from
baseline Ki-67 index at day 21 and at surgery. There was no
significant difference in the magnitude of the decrease in Ki-67
from baseline to surgery between different groups. The degree
of cell proliferation measured before or after chemotherapy
was not able to discriminate clinical or pathological respond-
ers from non-responders. Clinical responders were more likely
to exhibit a reduction in Ki-67 index after one cycle of chemo-
therapy. This group also displayed larger relative decreases inAvailable online http://breast-cancer-research.com/content/8/3/R31
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cell proliferation after the first cycle of treatment (median -
50.6, range -73.0 to 93.3) than did non-responders (median -
5.3, range -43.4 to 57.7) (p  = 0.04). Paradoxically, Ki-67
expression at day 21 was greater in pathological responders
compared with non-responders, despite the fact that the dis-
tribution of pre-treatment Ki-67 LI was similar in both groups.
This observation seems counterintuitive because tumour
regression would be expected to be accompanied by a reduc-
tion in cell proliferation. However, there was no association
between clinical response and those patients who achieved a
partial pathological response. These findings underline the
uncertainty surrounding the optimum method of assessment
of response in biomarker studies and raise concerns that one
(or perhaps both) of the classifications of response used in
this study may not be a reliable surrogate endpoint.
Table 2
Logistic regression analysis showing significant associations for prediction of response by different modalities of assessment and 
response classifications
Response variable p value
Pathological response (R/NR)
Ki-67 D21 0.0616
AI D21 0.0497
AI Sx 0.0620
Pathological CR
Not assessable -
'Near' pathological CR
No significant associations -
Clinical response (CR/PR/SD/PD)
[Path T stage T1 versus T3 0.0028]
Ki-67 D21 0.0097
AI D21 0.0224
Clinical response (CR/PR/NR)
[Path T stage T1 versus T3 0.0066]
Ki-67 D21 0.0326
AI D21 0.0224
Clinical response (R/NR)
Ki-67 D21 0.0323
Clinical CR
No significant associations -
Radiological response (R/NR) -
No significant associations
Mammographic response (CR/PR/SD/PD)
No significant associations -
USS response (CR/PR/SD/PD)
No significant associations -
Worst radiological response (CR/PR/SD/PD)
AI biopsy 0.0418
Worst radiological response (CR/PR/NR)
No significant associations -
AI, apoptotic index; CR, complete response;D21, day-21; NR, non-responder; PD, progressive disease; PR, partial response; R, responder; SD, 
stable disease; USS, ultrasound scan.Breast Cancer Research    Vol 8 No 3    Burcombe et al.
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More than half the patients showed an increase in measured
cell proliferation between day 21 and surgery. In responding
patients, the reduction in Ki-67 index after one cycle of treat-
ment was not sustained and was often followed by a rebound
increase in cell proliferation by the time of surgery (responders
26.8, range 2.4 to 48.0; non-responders 18.9, range 6.8 to
50.4).
The observed changes in proliferation during treatment may
have implications for determining the optimum duration of neo-
adjuvant chemotherapy prior to surgery for operable primary
breast cancer. Recently published randomised clinical trials
suggest that the addition of sequential taxane chemotherapy
after four cycles of anthracycline PST increases clinical and
pathological response rates and translates into improved over-
all survival [15,42]. The rebound increases in cell proliferation
noted after six cycles of anthracycline treatment in this study
may partly explain the superior clinical results achieved when
patients are switched to non-cross-resistant chemotherapy
regimens midway through neoadjuvant treatment. This phe-
nomenon warrants further investigation to establish whether
changes in tumour cell kinetics during treatment can identify
which patients are most likely to benefit from sequential chem-
otherapy schedules.
Wide variations in AI were seen both during and after chemo-
therapy. The non-significant trend toward increased AI in path-
ological responders at day 21 was confirmed by the logistic
regression analysis showing that increased day-21 AI is a sta-
tistically significant predictor of pathological response. This
observation suggests that tumours exhibiting high levels of cell
death after one cycle of chemotherapy are more likely to
achieve pathological regression. The high AI seen in the two
near-pCR patients at operation indicates that increased apop-
tosis after chemotherapy may also predict which patients will
have a good pathological response. Analysis of a larger cohort
is required to explore this hypothesis further. The magnitude of
changes in AI during treatment did not predict clinical, radio-
logical, or pathological response to treatment.
The optimum time point for detecting early cell kinetic changes
that may predict clinical and pathological outcomes is
unknown. Other groups have repeated FNA cytology 10 days
after chemoendocrine treatment [37,38]. Day 21 was arbitrar-
ily chosen as a convenient time in this study, to coincide with
patients' return to hospital for their second cycle of chemother-
apy, although there are no convincing data that it is the most
appropriate time to test biomarkers. It is possible that 21 days
after chemotherapy is too late to observe the peaks of apop-
totic response and suppression of proliferation induced by
cytotoxic treatment; there may be earlier times when the bio-
logic response to treatment is more critically related to thera-
peutic outcome. Indeed, there is some evidence that apoptotic
response after chemotherapy lasts for several days only [43-
45]. Ideally, serial biopsies may help to chart the precise pat-
tern of changes in biological markers during treatment; realis-
tically, however, large studies of this type are impractical,
because few patients are likely to agree to repeated invasive
tumour biopsies.
It is important to recognise the potential limitations of this
study. Like most published series in this field, the number of
patients reported is small. The use of tumour biopsies to
assess molecular marker expression before and after treat-
ment has become increasingly widespread as the search for
predictive markers for neoadjuvant chemotherapy continues.
Critics initially argued that this approach was subject to sam-
pling error and intra-tumour variability. However, the widely
quoted validation study by Ellis and colleagues [35] demon-
strated that core biopsies accurately reflect the expression of
biological markers in whole tumour sections.
In addition to clinical response, a novel descriptive histological
response analysis was used to grade pathological response in
this study. Although this system has not been prospectively
validated or proven to relate directly to survival, the strong
body of evidence that pCR is a good prognostic indicator for
long-term survival justifies its use. Unfortunately, the analysis
was hampered by the absence of complete pathological
responders in this small series, forcing the authors to adopt
the more widely used assessment of clinical response as an
endpoint.
Conclusion
In this small study, pre-treatment or post-chemotherapy
median Ki-67 index, median AI at all three time points, and rel-
ative changes at day 21 and surgery did not differ significantly
between clinical or pathological responders and non-respond-
ers. Clinical responders achieved significantly greater percent-
age reductions in Ki-67 and lower median Ki-67 indices at day
21 than did non-responders. Pathological responders dis-
played higher median day-21 Ki-67 expression. Increased day-
21 AI was a statistically significant predictor of pathological
response. A strong trend for predicting pathological response
was seen with higher Ki-67 indices at day 21 and AI at surgery.
The clinical utility of early changes in biological marker expres-
sion during chemotherapy remains unclear. For the time being,
clinical decision-making should not be based upon individual
biological tumour marker profiles until further prospectively val-
idated evidence confirming the reliability of predictive markers
is available. In the meantime, large prospective clinical trials of
neoadjuvant chemotherapy should include parallel biological
marker studies to facilitate immunohistochemistry and microar-
ray analysis on histological tissue taken at various time points
before, during, and after neoadjuvant chemotherapy to con-
tinue the search for clinically useful predictive biomarkers.
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